Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5283434
Max Phase: Preclinical
Molecular Formula: C57H106O15
Molecular Weight: 1031.46
Associated Items:
ID: ALA5283434
Max Phase: Preclinical
Molecular Formula: C57H106O15
Molecular Weight: 1031.46
Associated Items:
Canonical SMILES: CCCCCCCCCCCCCCCCCCC/C=C/C(=O)OC[C@H](CO[C@@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H](O)[C@H]1O)OC(=O)CCCCCCCCCCCCCCCCCCC
Standard InChI: InChI=1S/C57H106O15/c1-3-5-7-9-11-13-15-17-19-21-22-24-25-27-29-31-33-35-37-39-48(59)67-42-45(70-49(60)40-38-36-34-32-30-28-26-23-20-18-16-14-12-10-8-6-4-2)43-68-56-55(66)53(64)51(62)47(72-56)44-69-57-54(65)52(63)50(61)46(41-58)71-57/h37,39,45-47,50-58,61-66H,3-36,38,40-44H2,1-2H3/b39-37+/t45-,46-,47-,50+,51+,52+,53+,54-,55-,56-,57+/m1/s1
Standard InChI Key: FPBOHGQTFPCPBD-WIGFTALISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1031.46 | Molecular Weight (Monoisotopic): 1030.7532 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Govindarajan M.. (2018) Amphiphilic glycoconjugates as potential anti-cancer chemotherapeutics., 143 [PMID:29126728] [10.1016/j.ejmech.2017.10.015] |
Source(1):